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Histone deacetylases (HDACs), originally described as histone modifiers, havemore recently
been demonstrated to target a variety of other proteins unrelated to the chromatin environ-
ment. In this context, our present work demonstrates that the pharmacological or genetic
abrogation of HDAC6 in primary melanoma samples and cell lines, down-regulates the
expression of PD-L1, an important co-stimulatory molecule expressed in cancer cells, which
activates the inhibitory regulatory pathway PD-1 in T-cells. Our data suggests that this novel
mechanism of PD-L1 regulation is mainly mediated by the influence of HDAC6 over the
recruitment and activation of STAT3. Additionally, we observed that selective HDAC6 inhib-
itors impairs tumor growth and reduce the in vivo expression of several inhibitory check-
point molecules and other regulatory pathways involved in immunosurveillance. Most
importantly, these results provide a key pre-clinical rationale and justification to further
study isotype selective HDAC6 inhibitors as potential immuno-modulatory agents in cancer.
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clinical outcomes observed in patients receiving targeted ther-
apies aiming to block negative immuno-modulatory pathways
such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-
4), program death receptor-1 (PD-1) and program death recep-
tor ligand-1 (PD-L1) receptors (Hodi et al., 2010; Topalian et al.,
2012), ultimately, augmenting T-cell anti-tumor activity. This
work has paved a novel role in the development of rational
combinatorial approaches aimed at augmenting the efficacy
of immuno-modulatory drugs and antibodies targeting immu-
nological checkpoints. An emerging awareness is currently
addressing the role of epigenetic modifiers in the regulation
of immuno-modulatory pathways. Among these, histone
deacetylases (HDACs) are attractive targets due to the avail-
ability of a broad spectrum of inhibitors targeting their enzy-
matic activity (HDACi). However, despite the well
documented effects of HDACi in the control of the cell cycle
and apoptosis, their participation in the regulation of
immune-related pathways is still not completely understood.
Additionally, the reported immunological outcomes when us-
ing these drugs are heterogeneous, and in many cases contra-
dictory when using different HDAC inhibitors (Woan et al.,
2012; Tomasi et al., 2006). This lack of understanding and
the observed disparities in HDAC inhibition can be attributed,
at least in part, to the non-specific action of pan-HDACi target-
ing all 11 zinc-dependent HDACs, or a subset thereof, and the
intrinsic variations in the expression of these enzymes among
different cell types in both physiological and pathological con-
ditions. Therefore, the generation of selective HDACi and
mechanistic insight into their role in the immune response
against cancer cells are highly desirable goals, and has the po-
tential to augment anti-tumor immunity.
HDACs, originally described as histone modifiers, have
recently been demonstrated to modify a variety of other pro-
teins involved in diverse cellular processes unrelated to the
chromatin environment. This includes deacetylation ofmulti-
ple non-histone targets, such as members of oncogenic- and
immune-related pathways (Woan et al., 2012; Villagra et al.,
2010). In this regard, a considerable number of reports have
analyzed the role of unspecific inhibition of HDACs through
pan-HDACi in cancer as well as processes of immune regula-
tion. However, the contribution of single HDACs is still poorly
understood and only a few reports identified the role of spe-
cific HDACs in these cellular processes. In this context, we
recently reported that the genetic and pharmacological inhibi-
tion of a single HDAC, HDAC6, resulted in decreased prolifer-
ation of melanoma cells in both in vitro and in in vivo models
(Woan et al., 2015). In addition to this effect on survival,
HDAC6 was found to be a modulator of the expression of spe-
cific tumor associated antigens, MHC class I and co-
stimulatory molecules in melanoma (Woan et al., 2015).
Furthermore, HDAC6 seems to be an important regulator of
the STAT3 pathways (Cheng et al., 2014a), which is commonly
altered in melanoma and other malignancies (Yu et al., 2009).
Here, we report that HDAC6 is also involved in the regulation
of the co-inhibitory molecule Program Death Receptor Ligand
1 (PD-L1). This protein is one of the natural ligands for the PD-1
receptor present on T-cells, which suppresses T-cell activa-
tion, proliferation, and induces T-cell anergy and apoptosis
(Taube et al., 2014). During the last few years, a number ofimportant studies demonstrated that PD-L1 is present on can-
cer cells (Tomasi et al., 2006; Pardoll, 2012), and its over-
expression is often associated with poor prognosis in several
malignancies, including melanoma (Hino et al., 2010), ovarian
(Hamanishi et al., 2007), gastric (Wu et al., 2006) and breast
cancer (Ghebeh et al., 2006), among many others.
The already described participation of HDAC6 as regulator
of immune-related pathways inmelanoma and its new role as
PD-L1 regulator opens the possibility of using its selective in-
hibition as a potential immuno-modulatory option in ongoing
therapies aiming to ameliorate negative pathways affecting
the T-cell response against cancer.2. Materials and methods
2.1. Mice
Experiments involving mice were performed in accordance
with approved protocols by the IACUC at the University of
South Florida. C57BL/6 mice were obtained form the National
Institutes of Health (Fredrick, Maryland, USA). For in vivo tu-
mor studies, mice were subcutaneously injected into the
shaved flank with 1.3  105 B16-F10 melanoma cells sus-
pended in 100 mL Hank’s buffered salt solution (HBSS).
2.2. Patient samples
Patient-derived resectedmelanoma specimens were obtained
from Dr. Sarnaik’s Lab at Moffitt Cancer Center through a Uni-
versity of South Florida Institutional Review Board-approved
regulatory protocol. The cells were extracted directly from
melanoma tumor and cultured in RPMI 1640 supplemented
with L-glutamine, 10% FBS, 100 IU/mL Penicillin, 100 mg/mL
Streptomycin, 1% sodium pyruvate, 1% non-essential amino
acid, 0.05 mM of 2-mercaptoethanol and 1% gentamycin.
The cells were grown under humidified conditions at 37 C
and 5% CO2.
2.3. Cells
B16-F10-luc murine melanoma cell line was obtained from
ATCC and cultured in RPMI 1640 supplemented with 10%
FBS, 100 IU/mL Penicillin, and 100 mg/mL Streptomycin. SM1
cell line was obtained from Dr. Antoni Ribas’s Lab at Univer-
sity of California Los Angeles. Human melanoma cell lines
were obtained fromDr. Smalley’s Lab atMoffitt Cancer Center.
Cells were cultured in RPMI 1640 media, supplemented with
10% FBS, penicillin/streptomycin (50 U/ml), L-glutamine
(2 mM), and 2-mercaptoethanol (50 mM) (complete media),
and grown under humidified conditions at 37 C and 5% CO2.
2.4. HDACi
MGCD0103 and LBH589, were purchased from Selleck Chemi-
cals. The HDAC6 selective inhibitors Tubastatin A and Nex-
turastat B were synthesized by Dr. Alan Kozikowski
(University of Illinois, Chicago, IL). All HDACi were reconsti-
tuted in DMSO at greater than 10 mM and stored in aliquots
at 80 C. For in vitro use, stocks were diluted in complete
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stat B was dissolved in 5%DMSOplus 95%Hank’s buffered salt
solution (HBSS) 1X.2.5. Immunoblotting
The cells were lysed in a buffer containing 280 mM NaCl,
50 mM Tris HCL PH 8.0, 0.5% Igepal, 5 mM MgCl2, 10% glycerol
and 1X protease inhibitor (Roche), phosphatase inhibitor
(Santa Cruz Biotechnology). Lysates were sonicated on ice
for 8 min (2 cycles of 30 s on, 30 s rest) and then mixed with
6x gel loading buffer and boiled for 5 min. Samples were
then resolved on 10% or 4e15% gradient gels and transferred
to nitrocellulose membranes. Membranes were blocked with
5% milk-PBS-Tween. Bands were detected by scanning blots
with an LI-COR Odyssey imaging system using both 700 and
800 channels. The antibodies used for immunoblotting
included anti-acetyl-a-Tubulin (SC-23950) and anti-a-Tubulin
(SC-32293), which were purchased from Santa Cruz Biotech-
nology. Anti-HDAC6 (C0226) was from Assay Biotech. Anti-
GAPDH (68795) was from Sigma Aldrich. Anti-STAT3 (12640),
anti P-STAT3 Y-705 (9138), anti P-STAT3 S727 (9136), and anti
Acetil-STAT3 (2523) were purchased from Cell signaling. Anti
PD-L1 (PA5-28115) was obtained from Thermo Scientific.
Anti-FLAG (F1804) antibody was from Sigma.2.6. Flow cytometry
For surface marker analysis, wild type melanoma cells were
treated with Tubastatin A, Nexturastat B, or DMSO for 24 h,
and NT and HDAC6KD cell lines were maintained in growth
medium. All the cell lines after the treatment were incubated
for an extra 24 h with either IL6 (30 ng/ml) or IFN gamma
(100 ng/ml). Cells were rendered into single cell suspension
and stained with phycoerythryn (PE) conjugated antibodies
against PD-L1 (CD274). Conjugated antibodies were purchased
from BDBioscience, human PD-L1 (557924) and murine PD-L1
(558091). After staining for 30 min at 4 C, cells were washed
three times and then resuspended in buffer containing DAPI
(50 ng/mL) for viability. At least 10,000 events were collected
using an LSR II (BD) and subsequently analyzed using FlowJo
software.2.2.7.2.7. Generation of stable knockdown clones
shRNA lentiviral transduction particles for murine HDAC6
(NM010413, TRCN0000008415), for human HDAC6 (NM00604,
TRC0000004839) and non-target shRNA (SHC002V) were ob-
tained from Sigma Aldrich (St. Louis, MO). Transductions
were performed according to themanufacturer’s instructions.
Melanoma cells were grown in antibiotic-free medium and
transduced with shRNA particles in the presence of hexadi-
methrine bromide. After 72 h, puromycin was added to the
culture media and cells were cultured until 50% confluence
and analyzed for HDAC6 expression. Monoclonal populations
were generated by serial dilutions of polyclonal populations.
Multiple colonies were selected and tested to ensure the
reproducibility of effects from knocking down HDAC6 and
not an effect of individual clones.2.8. Protein over-expression experiments
Over-expression of HDAC6-flag and STAT3C-flag and respec-
tive control vectors were performed in WM164 human mela-
noma cell line. Cells were transfected using Lipofectamine
2000 (Invitrogen) according to the manufacturer’s protocol.
The cells were transfected with plasmids for 24 h, followed
by 24 h stimulation with the respective cytokine cells express-
ing each protein variant were treated for their further anal-
ysis; lysed and immunoblotted or the cells were collected for
flow cytometer analysis.
2.9. Reagents and plasmids
The recombinant cytokines human IL-16 (570804), human IFN-
gamma (570204), mouse IL-6 (575704), mouse IFNgamma
(575304) were purchased from Biolegend. Lipofectamine 2000
was purchased from Invitrogen. The over-expression plasmid
HDAC6-flagwere kindly provided by Dr. Zhang’s lab at Univer-
sity of South Florida, and the STAT3C-flag plasmid were ob-
tained from Addgene (24983).
2.10. Quantitative real-time RT-PCR
Melanoma cells were plated at 2  106 cells per 35 mm well
and cultured under conditions detailed above. The total RNA
was extracted from cells using TRIzol as per manufacturer’s
instructions (Invitrogen, NY). Briefly, cells were completely
homogenized in TRIzol reagent by pipetting and incubation
for 5 min at room temperature. Samples were then processed
immediately or stored at80 C. RNAwas extracted by chloro-
form and RNA precipitated from the aqueous phase using iso-
propyl alcohol. The RNA pellet was then washed with 75%
ethanol, air dried, and suspended in DEPC-treated water.
RNA was quantified spectrophotometrically using a Nano-
drop. 260/280 and 260/230 ratios were routinely over 1.8. The
cDNA was produced using iScript cDNA synthesis kit (Bio-
Rad, Hercules, CA). Target mRNA was quantified using MyIQ
single color real time PCR detection system (Bio-Rad) and iQ
SYBR green Supermix (Bio-Rad, Hercules, CA) using previously
assayed parameters (Cheng et al., 2014a, 2014b). Primers used
CDKN1A, IL-10, FOS and PD-L1 for qRT-PCR were purchased
fromQiagen and the cycling conditionswere used as perman-
ufacturer’s instructions. Single product amplification was
confirmed by melting curve analysis and primer efficiency
was near 100% in all the experiments performed. Quantifica-
tion is expressed in arbitrary units and target mRNA levels
were normalized to GAPDH expression using the method of
Pfaffl (Pfaffl, 2001).
2.11. In vivo studies
Mice received 1.3  105/mouse B16 tumor cells B16-F10-Luc
subcutaneously in a shaved rear flank. Once the tumor was
barely palpable Nexturastat B was injected daily intraperi-
toneally at a dose of 25 mg/kg. Tumor growth was moni-
tored every 2 days in individually tagged mice by
measuring the longest diameter (length) and the orthogonal
diameter (width) with calipers. Mice were euthanized when
the tumor volume reached 4000 mm3
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mean tumor size (volume in mm3) and standard deviation
for every treatment group at various time points until the
termination of the experiment.
Chromatin Immunoprecipitation (ChIP) assays. ChIP studies
were performed as previously described (Cheng et al.,
2014a). All steps were carried out at 4 C using WM164 mela-
noma cells: wild type, non target, KDHDAC6 or KDSTAT3. The
DNA was recovered using Qiagen (51304) Quiaquick
columns.
The antibodies used for CHIP experiments were obtained
as follows. Anti-HDAC6 (07-732), anti-STAT3 (06-596), anti-
Acetyl-Histone3 (06-599) were purchased from Millipore. The
anti-RNA Polymerase II CDT (ab817) was obtained from
Abcam. The 14 different sets of primers used for the PD-L1
promoter analysis are described in Table 1.
All samples and inputs were quantified using MyIQ single
color real time PCR detection system (Bio-Rad) and iQ SYBR
green Supermix (Bio-Rad). Single product amplification was
confirmed by melting curve analysis and primer efficiency
was near or close to 100% in all experiments performed. Quan-
tification is expressed in arbitrary units indicating fold over
non-stimulation condition, and target sequence levels were
normalized to the input signal using the method of Pfaffl
(Pfaffl, 2001). All ChIP experiments were repeated twice start-
ing from the crosslinking, and final quantitative real time PCR
was done in triplicates.Table 1 e Primers used for chromatin immunoprecipitation.
Primer
name
Sequence 50 30 Location in
PD-L1 promoter
A-FW TGTGGATTTGCTTTAATCTTC UTR
A-RV AGGTATCTAGTGTTGGTGTCCT
B-FW CATTTCTATACACAGCTTTATTCC UTR
B-RV CAAGGCAGCAAATCCA
C-FW TGTTTCACTTTCTGTTTCATTT 193/82
C-RV GTTGGACTTTCCTGACCTT
D-FW TCAGATGTTGGCTTGTTGT 312/192
D-RV CATGTCAGTCCAGTTTTCTTG
E-FW GCTGCTGACTTTTTATATGTTG 469/312
E-RV ACGCACCTTGATTTTACCT
F-FW AAAGATGTAGCTCGGGATG 783/632
F-RV GTGTGTGTGTGTATGGGTGT
G-FW ACACCATCGTCTGTCATCTT 959/832
G-RV CATCCCGAGCTACATCTTT
H-FW CAACGAAGAGTCCAATTTCT 1153/956
H-RV TTCTCGAACTCCTTGACCT
I-FW CATGCTCCTGCCAAATC 1267/1123
I-RV TTGTTTGCCTTTCCTTCTT
J-FW ACAGTCACCAAAATTGCTCT 1728/1588
J-RV CTGACACTGCCTTGATTTG
K-FW CAAAAACAAAATACCCATCC 1931/1804
K-RV TCAGAGCCATCTACCACTAAC
L-FW TTGTATGGGAAAATGAATGG 2035/1861
L-RV GATGGGAATTGAGGGTATTT
M-FW CCCACTCATTAACCATCTGT 2180/2010
M-RV GTGAGGATTCGTGTTTTTGT
N-FW CATGAATAGGAAGTGGTGGT 2449/2271
N-RV GCAAAACAGATGGTTAATGAG2.12. Statistical analysis
All experiments were repeated at least two times unless indi-
cated otherwise. Unpaired t-tests were performed using
Microsoft Excel Software (Microsoft, Redmond, WA) with sig-
nificance at p < 0.05.3. Results
3.1. HDAC6 modulates the activation of the STAT3
pathway
We recently reported the important role of HDAC6 in the regu-
lation of the STAT3 pathway in antigen presenting cells (APC)
(Cheng et al., 2014a). Although, the exact regulatory mecha-
nism is not completely understood, it was observed that the
pharmacological inhibition and genetic abrogation of
HDAC6, impairs the phosphorylation of STAT3 and subse-
quently inactivates STAT3 target genes, including number of
cytokines and immune-related genes (Cheng et al., 2014a).
Since, the deregulation of STAT3 has been described to be
important in the pathogenesis of melanoma (Messina et al.,
2008), we interrogatedwhether the effect of HDAC6 in the acti-
vation of STAT3 could be recapitulated in melanoma tumor
cells. Using specific HDAC6 shRNA lentiviral constructs we
created stable monoclonal cell lines lacking HDAC6
(HDAC6KD) in the human melanoma cell lines WM164,
WM983A and WM793. Next, we evaluated the activation of
the STAT3 pathway in these knock-down cells in parallel to
their respective homologous control cells transduced with
non-target shRNA (NT). As shown in Figure 1A, the absence
of HDAC6 impaired the proper phosphorylation of the
STAT3-Tyr705 after IL-6 stimulation, suggesting that the role
of HDAC6 in the activation of STAT3 was not restricted to
APCs, and may be a global regulatory mechanismmodulating
the activity of this pathway. In parallel, we evaluated the
phosphorylation of STAT3-Ser727, which has been described
to be essential for enhanced activation of STAT3 (Sakaguchi
et al., 2012), and an important post-translational modification
in the melanocytic lineage (Sakaguchi et al., 2012). Similarly,
the phosphorylation of this residue was diminished in the
absence of HDAC6. However, this occurred to a lesser extent
when compared to Tyr705 (Figure 1A).
Another post-translational modification reported as
important in the regulation of STAT3 is the acetylation of
Lys685 (Ray et al., 2008; Z-lGuan et al., 2005). Therefore, we
tested the possible participation of HDAC6 in this process by
analyzing the acetylation status of this particular residue.
However, we did not find major changes when comparing
HDAC6KD against their NT control cell lines (Figure 1A, anti
ac-STAT3). To further study the consequences of the inactiva-
tion of the STAT3 pathway in the absence of HDAC6, we eval-
uated the expression of well-characterized STAT3 target
genes (Cheng et al., 2014a) in melanoma cell lines. As shown
in Figure 1B, the expression of CDKN1A, IL-10 and c-FOS was
significantly reduced in the HDAC6KD cell lines when
compared with their respective NT controls. Importantly,
these differences were more evident in the IL-6 stimulated
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expression of these genes is mainly due to the inactivation
of the STAT3 pathway.
3.2. Enhanced interaction of STAT3 and PP2A in the
absence of HDAC6
We previously reported the interaction of HDAC6 with STAT3
in macrophages (Cheng et al., 2014a). Extending this previous
observation, and using a similar experimental approach, we
detected that this interaction occurred also in melanoma cells
(Figure 1C, aSTAT3). However, our results indicate that despite
this interaction, HDAC6 does not alter the acetylation status of
STAT3 (Figure 1A, aac-STAT3). Then, we explored other poten-
tial molecular mechanisms that might explain the participa-
tion of HDAC6 in the phosphorylation of STAT3. Our
attention was directed to the identification of a possible inter-
action of HDAC6 with JAK2, Shp-2 and PP2A, proteins directly
involved in the homeostasis of phospho-STAT3 (Murray, 2007;
Yu et al., 2014). As shown in Figure 1C, wewere able to detect a
physical interaction of HDAC6 with these three candidates.
Therefore, we next ventured to evaluate them as potential
enzymatic targets for HDAC6. Since, there are no available an-
tibodies for the acetylated variants of these proteins, our
experimental approach consisted of the immunoprecipitation
of all acetylated proteins from NT (control) and HDAC6KD
cells and then evaluating for these specific targets in the
immunoprecipitated fraction. As shown in Figure 1D, we did
not find any changes in the acetylation of PP2A, Shp-2 and
JAK2 proteins in the absence of HDAC6. In order to verify
this technique, we evaluated the acetylation of Hsp90, a
known target for HDAC6 (Boyault et al., 2007), which was
found to be hyperacetylated in the absence of HDAC6
(Figure 1D).
Another proposed regulatory mechanism affecting the ac-
tivity of STAT3 is its ability to interact with PP2A. In this re-
gard, it has been shown that histone deacetylase 3 (HDAC3)
functions as a scaffold protein to enhance the interaction of
STAT3 and PP2A, and subsequently down-regulates the
expression of STAT3 target genes (Togi et al., 2009). Consid-
ering this antecedent, and in order to evaluate the potential
participation of HDAC6 in the stability of the protein complex
STAT3-PP2A, we performed a co-immunoprecipitation of
STAT3 in the presence or absence of HDAC6. The analysis of
the immunoprecipitated fraction suggested that HDAC6 was
not essential for the interaction of STAT3 with Jak2 and Shp-
2 (Figure 1E). However, we observed an enhanced interaction
of STAT3 with PP2A in the absence of HDAC6 (Figure 1E,
aPP2A), suggesting that the effect of HDAC6 in the phosphor-
ylation of STAT3 could be mediated by this mechanism.
It has been demonstrated that STAT3 needs to be phos-
phorylated in order to allow its dimerization and subsequent
translocation to the nucleus (Yu et al., 2014). Since our results
indicate that HDAC6 is necessary for STAT3 phosphorylation,
we hypothesized that the intracellular localization of STAT3
was also affected in the absence of HDAC6. To further explore
this possibility, we analyzed nuclear and cytosolic extracts
fromNT and HDAC6KDmelanoma cells previously stimulated
with IL-6. As expected, the presence of STAT3 in the nucleus
increased after IL-6 treatment in NT cells. However, inHDAC6KD cells we found minimal differences between the
stimulated and non-stimulated conditions (Figure 1F, nuclear
panel).3.3. HDAC6 is necessary for the cytokine-mediated up-
regulation of PD-L1 expression
STAT3 regulates critical functions in mammalian cells, such
as proliferation, survival, differentiation, and immune
response, among others (Yu et al., 2014). Constitutive active
STAT3 has been observed in human melanoma cell lines
and primary tumors, but not in matched normal skin speci-
mens from the same patients (Niu et al., 2002a). In fact, it
has been shown that hyperactivity of STAT3 deregulates the
expression of several important immune-related pathways,
including those involved in the regulation of pro- and anti-
inflammatory pathways and anti-tumor responses (Woan
et al., 2012; Villagra et al., 2010; Yu et al., 2009). It has been re-
ported that STAT3 is a potent activator of the co-stimulatory
molecule PD-L1 in antigen presenting cells (APCs) (Wolfle
et al., 2011) and in melanoma (Jiang et al., 2013). In order to
validate these early observations we evaluated the expression
of PD-L1 in STAT3 knock-down (STAT3KD) in the same
parental melanoma cell lines that were used to generate the
HDAC6KD monoclonal cell lines. As expected, the expression
of PD-L1 in NT control cells was enhanced upon IL-6 stimula-
tion. However, its expression was importantly diminished in
the STAT3KD cells after IL-6 stimulation (Figure 2A). Analysis
of the PD-L1 mRNA by qRT-PCR confirmed that our observa-
tions were due to transcriptional regulation and discarded
any potential post-translational regulatory mechanism
affecting the presence of the PD-L1 (Figure 2B).
Our results also suggest that HDAC6 is absolutely neces-
sary for the phosphorylation of STAT3. Consequently, we ex-
pected that HDAC6 might also indirectly control the
expression of PD-L1 by modulating the activation of STAT3.
In order to test this hypothesis, we evaluated the expression
of PD-L1 mRNA in HDAC6KD melanoma cells stimulated
with either IL-6 or IFNg. As shown in Figure 2C, after cytokine
stimulation, the expression of PD-L1 increased between 2.5
and 4 times over the non-stimulated condition assigned as
value 1.0 on each chart. While the absence of HDAC6 slightly
diminished the expression of PD-L1 in the non-cytokine treat-
ment, we observed an important abrogation in its production
after the stimulation with both cytokines. However, this effect
was more pronounced in the IL-6 treatment when compared
to the IFNg stimulation, which has been reported previously
to be a potent activator of PD-L1 expression in professional an-
tigen presenting cells (APCs) (Loke and Allison, 2003). To
further study whether the diminished expression of PD-L1
mRNA was also affecting the protein levels of this co-
stimulatory molecule, we evaluated the total amount of PD-
L1, which was found to be also substantially diminished in
HDAC6KD cell lines after stimulation with IL-6 (Figure 2D).
Likewise, changes in PD-L1 protein were similar when we
evaluated the expression of surface PD-L1 on HDAC6KD mel-
anoma cells by flow cytometry (Figure 2E, HDAC6KD). In paral-
lel, we evaluated the presence of surface PD-L1 in STAT3KD
melanoma cells, demonstrating a similar decrease of its
Figure 1 e The absence of HDAC6 impairs the STAT3 activation in melanoma cells. (A) NT and HDAC6KD WM164, WM983A and WM793
melanoma cells were treated with IL-6 (30 ng/mL) or left untreated. Then, the presence of HDAC6, acetylated tubulin, STAT3, P-STAT3Y705,
P-STAT3-S727, acetylated STAT3 and GAPDH was evaluated by immunoblot. (B) Total RNA was isolated from NT and HDAC6KD WM164
melanoma treated with IL-6 (30 ng/mL) or left untreated. Next, the expression of CDKN1A, IL-10 and FOS was analyzed by quantitative real-
time RT-PCR (qRT-PCR). The results are expressed as a percent over control cells, and data normalized by GAPDH expression. This experiment
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STAT3KD).
3.4. The recruitment of STAT3 to the PD-L1 promoter
precedes the transcriptional activation of PD-L1
The initial work describing the binding of STAT3 to the PD-L1
promoter in APCs only evaluated the recruitment of STAT3 at
the 200 bp PD-L1 proximal promoter region (Wolfle et al.,
2011). After performing amanual search of consensus binding
sites for STAT3 in the PD-L1 promoter (Ehret et al., 2001), we
identified several other potential binding sites along the first
2.5 kbp of the promoter region (578, 1113, 1812, 1929,
2182 and 2429 bp) (Figure 3A). This analysis suggested
that STAT3 could be a regulator of the expression of PD-L1
through multiple response elements on its promoter. Addi-
tionally, the regulation of PD-L1 in melanoma could obey
different molecular mechanisms in comparison to those
encountered in APCs, such as differential presence/activation
of cellular pathways and/or intrinsic variations in the chro-
matin accessibility. Therefore, we decided to evaluate the
recruitment of STAT3 to all these potential binding sites at
the PD-L1 promoter in the humanmelanoma cell lineWM164.
Of note, the kinetics for the recruitment of STAT3 to the
PD-L1 promoter has not been explored previously. Therefore,
we performed chromatin immunoprecipitation (ChIP) of
STAT3 at several time points after IL-6 stimulation, starting
at 15 min up to 24 h. As shown in Figure 3B, we observed a
peak in STAT3 recruitment at 15 min, followed by a decline
in its detection at 4 h, reaching similar levels to the non-
stimulated condition (time zero). Interestingly, we found a
new recruitment event starting at 6 h, and a sustained slight
increase up to 24 h post-stimulation. In a parallel experiment,
we determined that the phosphorylation of STAT3 occurs
shortly after IL-6 treatment, starting at 15 min and having a
maximal peak at 1 h, suggesting that STAT3 is recruited to
the PD-L1 promoter as soon is phosphorylated and subse-
quently activated (Figure 3C, anti-STAT3). We also measured
the PD-L1 protein production at the previously mentioned
time points, detecting its expression right after the activation
peak of STAT3 at 4 h post-stimulation with IL-6 (Figure 3C,
anti-PD-L1). This pattern in the PD-L1 production kinetics
was further explored by the analysis of the PD-L1 mRNA,
which demonstrated a peak at around 6 h (Figure 3D). Addi-
tionally, we observed that the recruitment of activated Pol II
(Supplementary Figure 1A) and hyperacetylation of histone 3
(ac-H3) (Supplementary Figure 1B) occurred after the recruit-
ment of STAT3 at 30 min and 2 h, respectively. These findings
suggest that the recruitment of STAT3 is an early event neces-
sary for the proper transcriptional activation of PD-L1was performed three times with similar results. Error bars represent standar
in WM164 cells. Cellular extracts were subjected to immunoprecipitation a
presence of Flag, STAT3, JAK2, Shp-2 and PP2A using specific antibodies.
HDAC6KD WM164 cells. The immunoprecipitated fraction was then assa
carrying Flag-STAT3 was transfected in WM164 cells. Then, cellular extr
immunoprecipitated fraction was assayed for the presence of Flag, HDAC6
cytoplasmic fractions were isolated from NT and HDAC6KDWM164 cells
B, GAPDH.expression. Another well characterized stimulator of PD-L1
production is IFNg (Supplementary Figure 1C). However, we
observed that this stimulus occurred after 12 h post-
stimulation, supporting an indirect mechanism mediated by
this cytokine (Supplementary Figure 1D).
3.5. The recruitment of STAT3 to the PD-L1 promoter is
impaired in the absence of HDAC6
We demonstrated previously that the interaction of HDAC6
with STAT3 in APCs is necessary for the STAT3 recruitment
to the IL-10 promoter (Cheng et al., 2014a). Therefore, we hy-
pothesized that HDAC6 might be also recruited to the PD-L1
promoter in melanoma. Following the same conditions
described for STAT3 in Figure 3B, we performed ChIP for
HDAC6, confirming that this deacetylase was recruited to
the PD-L1 promoter at the same time as STAT3 (Figure 3E).
Remarkably, the pattern of recruitment along the 2500 bp of
the promoter was similar to STAT3, as we observed an
enhanced recruitment between the 956 bp to 2429 bp
regions.
In order to further study, the relationship and interdepen-
dence of STAT3 andHDAC6, we evaluated their recruitment to
the PD-L1 promoter in the absence of each other. Briefly, as in
the preceding experiments, we used the human melanoma
cell line WM164, which was subjected to ChIP against STAT3
at 15 min post-stimulation with IL-6. As shown in Figure 3F,
STAT3was recruited to the PD-L1 promoter in NT control cells
following the same pattern observed in Figure 2B. However,
STAT3 was not detected at the PD-L1 promoter in the absence
of HDAC6, implying that HDAC6 is required for its recruit-
ment. Conversely, the same experiment was repeated in
STAT3KD cells, but this time we evaluated the presence of
HDAC6 at the PD-L1 promoter. As shown in Figure 3G, the
recruitment of HDAC6 was not completely impaired in the
absence of STAT3, suggesting that HDAC6 could be a partner
for another transcription factor involved in the regulation of
PD-L1.
3.6. PD-L1 expression is rescued upon constitutive
STAT3 activation in HDAC6KD melanoma cells
Next, we wanted to know whether the effect of HDAC6 over
the expression of PD-L1 was a consequence of its regulatory
role over the STAT3 activation ormediated by another cellular
event. In order to answer this question, we over-expressed a
constitutively active variant of STAT3 (STAT3c) which acti-
vates its target genes in the absence of cytokine stimulation
and independently of the activation status of the upstream
STAT3 pathway (Niu et al., 2002b). As expected, in the absenced deviation from triplicates. (C) HDAC6-flag plasmid was transfected
gainst flag. The immunoprecipitated fraction was then assayed for the
(D) Total acetylated proteins were immunoprecipitated from NT and
yed for the presence of PP2A, Shp-2Jak2 and Hsp90. (E) A construct
acts were subjected to immunoprecipitation against Flag. Next, the
, JAk2, Shp-2 and PP2A using specific antibodies. (F) Nuclear and
and immunoblotted against HDAC6, STAT3, p-STAT3 Y705, Lamin
Figure 2 e HDAC6 modulates the expression of PD-L1 in melanoma cells. (A) NT and STAT3KD WM164, WM983A and WM793 melanoma
cells were treated with IL-6 (30 ng/mL) or left untreated. The presence of STAT3, PD-L1 and GAPDH was evaluated by immunoblot. (B) Total
RNA was isolated from NT and STAT3KD WM164 melanoma treated with IL-6 (30 ng/mL) or left untreated. Then, the expression of PD-L1
was analyzed by quantitative qRT-PCR. The results are expressed as a percent over control cells, and data normalized by GAPDH expression.
This experiment was performed three times with similar results. Error bars represent standard deviation from triplicates. (C) Total RNA was
isolated from NT and HDAC6KD WM164 and WM793 melanoma cells treated with IL-6 (30 ng/mL), IFNg (100 ng/mL) or untreated. The
expression of PD-L1 was analyzed by quantitative qRT-PCR. These results are expressed as a percent over control cells, and data normalized by
GAPDH expression. This experiment was performed three times with similar results. Error bars represent standard deviation from triplicates. (D)
Immunoblotting analysis of PD-L1, acetylated tubulin and GAPDH proteins in NT and HDAC6KDWM164 and WM793 melanoma cells under
stimulation of IL-6 (30 ng/mL). (E) Expression of PD-L1 was measured by flow cytometry in NT, HDAC6KD and STAT3KD melanoma cell
lines with or without stimulation of IL-6 (30 ng/mL).
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of PD-L1 post IL-6 stimulation (Figure 4A). However, the pres-
ence of PD-L1 was rescued after the over-expression of
STAT3C in all tested conditions, NT, HDAC6KD and STAT3KD
(Figure 4B), demonstrating that STAT3 is a downstream target
in the inhibitory effect observed in the absence of HDAC6.
Similar results were also achieved after IFNg stimulation
(Supplementary Figure 1E and F).
3.7. HDAC6 selective inhibitors recapitulate the effect of
HDAC6 knock-down over the production of PD-L1
Acknowledging the requirement of HDAC6 for the proper acti-
vation of the STAT3 pathway and PD-L1 expression in mela-
noma cells, we analyzed whether the enzymatic activity of
this deacetylase is responsible for the observed outcome. In
order to test this hypothesis, we used the selective HDAC6 in-
hibitor Tubastatin A in melanoma cells. First, we evaluated
the acetylation status of tubulin, which has been described
as a quantifiable target to evaluate HDAC6 activity (Hubbert
et al., 2002). As expected, we observed a strong induction of
acetyl-tubulin in all human and mouse melanoma cell lines
tested (Figure 5A, ac-Tubulin), confirming the pharmacolog-
ical inhibition of HDAC6 under these conditions. The subse-
quent evaluation of STAT3 phosphorylation and PD-L1
production revealed that the enzymatic inhibition of HDAC6
mirrored the results previously found with the HDAC6
knock-down (Figure 5A, pSTAT3-Y705 and PD-L1). A reduced
presence of PD-L1 on the surface of melanoma cells was also
observed by flow cytometry, confirming the previous results
(Figure 5B). In order to determine if the effect mediated by
HDAC6 inhibitors was also occurring with other non-
selective inhibitors we evaluated the expression of PD-L1 in
melanoma cells treated with the pan-HDACi LBH589 and the
class I HDAC inhibitor MGCD0103. As shown in the
Supplementary Figure 2A and 2B, both inhibitors enhanced
the expression of PD-L1 in melanoma cells, suggesting that
these inhibitors might regulate PD-L1 expression through
other molecular mechanisms. It has been reported that class
I HDACs selectively deacetylate STAT3-Lys685, inactivating
the STAT3 pathway. Therefore, we hypothesized that the
enzymatic inhibition of these HDACs could enhance PD-L1
production by increasing the acetylation status of STAT3. In
order to test this possibility, we evaluated the activation of
STAT3 after treatment with LBH589 and MGCD0103 in
WM164 melanoma cells. As expected, both HDACi increased
the production of PD-L1 in a dose dependent fashion
(Supplementary Figure 2C and 2D, aPD-L1). Additionally, we
observed that the acetylation status of STAT3 increased after
treatment with HDACi, having a pronounced effect at a high
drug concentration (Supplementary Figure 2C and 2D, aac-
STAT3 685).
3.8. HDAC6 inhibition reduces tumor growth and PD-L1
production in vivo
Given the potent effect of HDAC6 disruption over the produc-
tion of PD-L1 in vitro, we asked whether this finding would
translate in vivo. As previously reported by our group (Cheng
et al., 2014a), we found an important delay in B16-F10 mousemelanoma tumor growth in mice treated with the HDAC6 in-
hibitors Nexturastat A (Figure 6A) or Tubastatin A (Figure 6B).
Additionally, and as we hypothesized, the drug treatment
impaired the phosphorylation of STAT3 and PD-L1 production
in all tumors isolated at the end point (Figure 6C), closely
resembling the abrogation induced after the in vitro genetic
or pharmacological inhibition of HDAC6 in B16-F10 cells. In
further analysis we treated cells obtained frommelanoma pa-
tient biopsies. As shown in Figure 6D, the treatment with the
selective HDAC6i Nexturastat diminished the STAT3 phos-
phorylation and the production of PD-L1, demonstrating that
this effect was not restricted to cell lines or mouse models.
3.9. The HDAC6 abrogation controls multiple immune-
related pathways and check-point molecules
In addition to the effect of HDAC6 inhibition over the expres-
sion of PD-L1, we previously observed that the genetic and
pharmacological inhibition of HDAC6 induced the expression
of MHC class I and several tumor associated antigens such as
gp100, MART1, TYRP1 and TYRP2 (Woan et al., 2015). There-
fore, we hypothesized that the overall effect of the HDAC6
manipulation could be the consequence of multiple pathways
affecting tumor growth, immune surveillance and anti-tumor
immune responses.
To investigate the participation of HDAC6 in the regulation
of other anti-tumor response mechanisms, we evaluated the
expression of several inhibitory check-point molecules and
other regulatory tumor receptors in the absence of HDAC6.
As shown in Figure 7A, the expression of total PD-L2, B7-H4
(inhibitory check-point molecule VTCN1) and TRAIL-R1 were
importantly diminished in the WM164 HDAC6KD cells, while
B7-H3 (inhibitory check-point molecule CD276), Galectin-9
and TRAIL-R2 were just slightly modified. In a parallel flow
cytometry experiment we confirmed that the presence of
PD-L2, B7-H4 and TRAIL-R1 in the cell surface was also
affected (Figure 7B). In further experiments, we assessed the
expression of the aforementioned surface proteins in primary
melanoma cells isolated from patient biopsies. As expected,
the expression of PD-L2, B7-H3 and TRAIL-R1 was diminished,
while the other proteins were modified in a lesser magnitude,
with the exception of B7-H4 that was strongly down-regulated
in the patient 3 (Figure 7C).4. Discussion
Recent clinical trials using PD-1 blocking antibodies have
demonstrated promising results in several malignancies.
However, not all patients respond equally to this treatment,
and the reported objective response rate (ORR) is 26% for pa-
tients diagnosed with advanced melanoma (Robert et al.,
2014), and 40% for patients diagnosed with wild type BRAF
melanoma (Robert et al., 2015). Additionally, a slight improve-
ment in the ORR has been found when using combined check-
point blockade agents, as reported for the combination of anti
PD-1 and anti-CTLA-4 blocking antibodies, where the ORR
increased to 40% (Callahan et al., 2014). As a result, there is a
special interest to identify new potential therapeutic options
and/or adjuvants targeting multiple cellular processes,
Figure 3 e HDAC6 and STAT3 are recruited to the PD-L1 promoter. (A) Schematic diagram of the PD-L1 promoter showing the potential
STAT3 binding sites and primers used in the ChiP assays. ChiP analysis of WM164 wild type melanoma cell line stimulated with IL-6 (30 ng/mL)
and collected at baseline (time 0) or at 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h after stimulation, assessed with HDAC6 (B) and STAT3 (E) antibodies,
followed by quantitative real-time PCR analysis of the 14 different primers described above (detailed in Table 1). (C) WM164 cells were treated
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Figure 4 e Constitutive active STAT3 rescue PD-L1 expression in the absence of HDAC6. NT, HDAC6KD and STAT3KDWM164 melanoma
cells were transfected with either STAT3C-flag plasmid (B) or empty vector (A) and then stimulated with IL-6 (30 ng/mL) or left untreated. Then,
PD-L1 was evaluated by flow cytometry.
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Figure 5 e Selective HDAC6 inhibitors down-regulate PD-L1
expression in vitro. (A) WM164, WM983A and WM793 human
melanoma cell lines were incubated with the HDAC6 inhibitor
Tubastatin A (3 mM) for 24 h, followed for IL-6 stimulation (30 ng/
mL). Then, the cells were lyzed and immunoblotted using the specific
antibodies listed in figure. (B) WM164 cells were treated with
Tubastatin A (3 mM), with or without stimulation of IL-6 and then
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 7 3 5e7 5 0 745thereby improving immunotherapeutic options in melanoma
treatment. Some HDACs have captured special attention due
to their recently assigned roles as modulators of oncogenesis
and the immune response (Woan et al., 2012; Villagra et al.,
2010; Kroesen et al., 2014). Among them, the genetic and/or
pharmacological inhibition of HDAC6 has been reported to
inhibit tumor growth in vitro and in vivo and control the
expression of tumor associated antigens and MHC class I in
melanoma (Woan et al., 2015). Additionally, HDAC6 is an
essential regulator in the activation of the pro-oncogenic
STAT3 pathway, and we previously demonstrated that selec-
tive inhibitors for this deacetylase effectively down-regulate
the expression of STAT3 target genes, such as IL-10 (Cheng
et al., 2014a). These findings, along with the important known
role of STAT3 hyperactivation in melanoma (Yu et al., 2009),
encouraged us to further study the potential involvement of
HDAC6 in the regulation of STAT3 target genes in this partic-
ular cancer. Our initial characterization focused in proving
that HDAC6was alsomodulating STAT3 Tyr-705 phosphoryla-
tion inmelanoma, whichwas evaluated across several human
cell lines (Figure 1A). Additionally, we found that the abroga-
tion of HDAC6 impaired the proper phosphorylation of
STAT3 Ser-727, whichwas not found to be affected in the orig-
inal work reporting HDAC6 as a modulator of STAT3 activa-
tion in APCs (Cheng et al., 2014a). Although, it was initially
suggested that Ser-727 phosphorylation is a secondary event
after Tyr705 phosphorylation, and only required for the
maximal transcriptional activity of STAT3 (Wen et al., 1995),
it is largely accepted now that this specific phosphorylationwith IL-6 (30 ng/mL) and then evaluated by immunoblotting for the presence of STAT3, pSTAT3, PD-L1 and b-Actin. (D) Following the same
conditions and time points from the previous experiment, RNA was isolated and the expression of PD-L1 analyzed by qRT-PCR. (E) ChiP
analysis of WM164 cells following the same conditions and time points described in experiment (B). NT, HDAC6KD, STAT3KD WM164 cells
with or without stimulation of IL-6 were subjected to ChIP and the presence of STAT3 (F) and HDAC6 (G) was evaluated after 15 min of IL-6
stimulation. The values obtained from all ChiP experiments were analyzed using the PfaffI method (Pfaffl, 2001) and are presented relative to
input before immunoprecipitation. Data presented is from one representative experiment out of two independent experiments with similar results
(error bars, s.d. of triplicates).
the expression of PD-L1 was analyzed by flow cytometry.
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Figure 6 e Selective HDAC6 inhibitors down-regulate PD-L1 expression in vivo. In vivo tumor growth of C57BL/6 mice injected subcutaneously
with B16-F10-luc WT cells. Mice were treated by intraperitoneal injection daily with the HDAC6 inhibitors Nexturastat 25 mg/kg (A) and
Tubastatin A 25 mg/kg (B). (C) Tumors were collected at the end point from C57BL mice either treated with Nexturastat or non-treated, and the
presence of HDAC6, STAT3, pSTAT3, PD-L1 and GAPDH was evaluated by immunoblot. (D) Cells from melanoma patient’s biopsies were
treated or untreated with Nexturastat (3 mM and 6 mM) and then the presence of HDAC6, STAT3, pSTAT3, PD-L1 and GAPDH was evaluated
by immunoblot.
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(Sakaguchi et al., 2012). Acetylation of STAT3 is also a regu-
lator of the STAT3 activity (Z-lGuan et al., 2005). In this regard,
previous reports did not find major changes in the acetylation
status of STAT3 in the absence or inhibition of HDAC6 inmacrophages (Cheng et al., 2014a), and similar results were
obtained in the present work (Figure 1A, anti ac-STAT3), sug-
gesting that HDAC6 might be controlling the phosphorylation
of STAT3 by indirect means. A potential alternative regulatory
mechanism is the previously reported action of additional
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 7 3 5e7 5 0748proteins affecting the interaction of STAT3 with the phospha-
tase PP2A (Togi et al., 2009). Our data clearly demonstrated
that a possible explanation for the impaired phosphorylation
of STAT3 in the absence of HDAC6 could be originated by
the enhanced interaction of PP2A with STAT3, which in turn
could facilitate the dephosphorylation of STAT3-mediated
by PP2A.
The significance of these findings is in line with several
other reports positioning STAT3 as a tolerogenic pathway
influencing both professional APCs and tumor cells to inhibit
T-cell function and evade immune recognition (Kortylewski
et al., 2005). In addition to STAT3, several other cellular path-
ways have been reported to be involved in the regulation of
PD-L1, including those activated by IL-6, IL-10, IL-4, GM-CSF,
TLRs, interferons and TNFa (Loke and Allison, 2003;
Francisco et al., 2010; Yamazaki et al., 2002). Among them,
IFNg has been reported as a potent stimulator of PD-L1 pro-
duction, a process believed to be mediated by the STAT1
pathway (Loke and Allison, 2003). Sincemost of the aforemen-
tioned observations have been made in immune cells, we
evaluated whether PD-L1 was also up-regulated by IFNg in
melanoma cells. As shown in Figure 2C, the stimulation of hu-
man melanoma cells with IFNg was closely comparable with
the values achieved using IL-6. In spite of that observation,
both stimuli were able to induce the expression of PD-L1 and
we observed that the negative effect of HDAC6KD over PD-L1
was more pronounced after IL-6 stimulation, suggesting that
HDAC6 was mainly regulating the STAT3 pathway and prob-
ably to a lessermagnitude STAT1, possibly by heterodimeriza-
tion of STAT3 and STAT1 as demonstrated previously (Haan
et al., 2005; Delgoffe and Vignali, 2013).
It has been reported that HDAC6 is recruited to regulatory
sequences in gene promoters such as MYC (Toropainen
et al., 2010), glucocorticoid receptor (Govindan, 2010) and es-
trogen receptor a-inducible genes (Palijan et al., 2009). Howev-
er, there is no evidence suggesting that HDAC6 directly affects
the acetylation status of chromatin. In fact, the deacetylation
of histones by HDAC6 has been demonstrated only by in vitro
assays (Todd et al., 2010). The transcriptional regulatory ef-
fects observed for HDAC6 could be mediated by other regula-
tory factors recruited along with this deacetylase to specific
DNA sequences. This hypothesis suggests that HDAC6 may
be a regulator of the activation status of these transcription
factors, perhaps by modulating their acetylation and/ormodi-
fying other essential regulators of these transcription factors.
We have previously observed that HDAC6 and STAT3 are
recruited to the same region of the IL-10 promoter, and the
recruitment of HDAC6 is impaired when cells are treated
with the STAT3 inhibitor CPA-7 (Cheng et al., 2014b). More-
over, the recruitment of STAT3 to the IL-10 promoter dimin-
ishes considerably in HDAC6KD cells, suggesting that the
down-regulation of PD-L1 expression in the absence or inhibi-
tion of HDAC6 could be part of a global regulatory mechanism
affecting STAT3 target genes.
As mentioned before, the recruitment of STAT3 to the PD-
L1 promoter has been shown previously in APCs. However,
thiswork only evaluated a very discrete region around the first
200 bp region of the PD-L1 promoter. Our search for consensus
potential STAT3 binding sites identified several regions along
the first 2.5 kbp of the PD-L1 promoter, which wedemonstrated by analyzing the recruitment of this transcrip-
tion factor to all the potential STAT3 binding sites using
ChIP. Interestingly, these results indicate that STAT3 and
HDAC6 were preferentially recruited to the far region
comprised between 956 bp and 2429 bp, suggesting that
this distal region could be responsible for the recruitment of
STAT3. Needless to say, future experiments aiming towards
the identification of single binding sequences are necessary
for a more detailed characterization of the STAT3 recruitment
to the PD-L1 promoter.
In addition to the role of HDAC6 in the modulation of
immune-related pathways, it has also been reported that
HDAC6KD melanoma cells have decreased proliferation
when compared to their respective controls, and this effect
ismainlymediated by G1 cell cycle arrest withminimal effects
in apoptotic signaling (Woan et al., 2015). As mentioned
before, selective HDAC6 inhibitors are currently available,
making this deacetylase a very attractive target to pursue us-
ing small molecules as potential anticancer drugs. In this
context, selective HDAC6 inhibitors, alone or in combination
with other agents, are currently under evaluation in clinical
trials, including the ongoing Phase 2 multiple myeloma clin-
ical trial using the partially selective HDAC6 inhibitor
ACY1215, which has shown important anti-tumor activity in
pre-clinical studies (Santo et al., 2012). The in vivo results pre-
sented in this work suggest that HDAC6 inhibitors are also
endowed with anti-tumor activity in melanoma, and this ef-
fect could be the result of themodulation ofmultiple regulato-
ry mechanisms involved in tumor survival and immune
recognition, including the down-regulation of PD-L1, PD-L2,
B7-H4 and TRAIL-R1. In overall, our results provide a rational
framework to consider the use of selective HDAC6 inhibitors
as anti-tumor agents in melanoma.Disclosures
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